Abstract library

14 results for "Benz".
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#119 Valproic acid induces apoptosis-mediated cell death of the ileal carcinoid cell line GOT1
Introduction: Downregulation of tumor suppressor genes, evasion from apoptosis, and reduced differentiation are hallmarks of cancer that can be due to abnormal epigenetic control. Histone deacetylase (HDAC) is an enzyme involved in the deacetylation of histone proteins, resulting in chromatin remodelling and altered gene transcription. HDAC inhibitors are emerging as useful anticancer drugs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Yvonne Arvidsson
Authors: Arvidsson Y, Ahlman H, Nilsson O, ...
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#356 Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis
Introduction: Carcinoid heart disease (CHD), a complication of NETs, is characterized by right heart fibrotic lesions. In addition to serotonin, cytokines and growth factors with fibrogenic properties may play a role.
Conference:
Category: Basic
Presenting Author: MD, PhD Deidi S. Bergestuen
#510 Salivary-Free Catecholamines Metabolites in Pheochromocytoma
Introduction: Salivary monitoring of hormone levels have many advantages over the more conventional serum/plasma analysis. Salivary-free metanephrines (MN) and normetanephrines (NMN) could improve biochemical diagnosis of pheochromocytoma (PHEO) as an alternative to plasma metabolites.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Corin Badiu
#936 Promoter Hypermethylation at RASSF1 is a Feature of Small Intestinal Neuroendocrine Tumors
Introduction: Promoter hypermethylation of RASSF1 has been reported in many tumor types.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis
#966 Evaluation of Lysyl Oxidase-Like-2 (LOXL2) Expression by Immunohistochemistry (IHC) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): A Retrospective Analysis and Comparison with PTEN
Introduction: A better understanding of the relationship between the stroma and the cancer cells of this group of malignancies remains a challenge. LOXL2 is an enzyme that contributes to the synthesis and stabilization of the cellular matrix and plays a role in angiogenesis.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Dr Jorge Barriuso
Keywords: LOXL2, GEP-NET
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova